20-F: Check-Cap Ltd. Faces Delisting Amid Strategic Shift, Nobul AI Merger

Check-Cap Ltd. is set to merge with Nobul AI Corp., potentially leading to its delisting from Nasdaq as it navigates financial challenges and strategic realignments.

Summary

• Check-Cap Ltd., a clinical-stage medical diagnostics company, is undergoing a strategic shift, including a merger with Nobul AI Corp.
• The merger, if completed, will result in Check-Cap's delisting from the Nasdaq Capital Market and deregistration under the Securities Exchange Act of 1934.
• Check-Cap has faced financial challenges, including a history of losses, leading to workforce reductions and a focus on essential research activities.
• The company's lead product, C-Scan, aimed at colorectal cancer screening, has encountered setbacks in clinical trials, prompting a re-evaluation of its development and commercialization strategy.
• The merger with Nobul AI Corp. is subject to shareholder and regulatory approvals, with potential adjustments to ownership percentages based on Check-Cap's net cash at closing.
• If the merger fails, Check-Cap anticipates needing significant additional funding to continue C-Scan's development, potentially requiring it to cease operations if funding is unavailable.
• Check-Cap's financial results for 2023 show a net loss of $17.6 million, with an accumulated deficit of $144.9 million as of December 31, 2023.
• The company's future is contingent on the successful completion of the merger or securing alternative strategic options and funding.

Sentiment

Score: 3

Explanation: The document presents a mixed outlook, with the potential merger offering a path forward but significant financial challenges and clinical trial setbacks weighing heavily on the company's prospects.

Positives

• The proposed merger with Nobul AI Corp. presents a potential strategic path forward for Check-Cap.
• The company is focusing its resources on essential research activities.
• Check-Cap has a CE-certificate from its notified body (DEKRA) according to the EU Regulation 2017/745 on Medical Devices for the marketing and sale of C-Scan in the European Union, valid until December 1, 2026.
• Check-Cap has approval from the Medical Devices and Accessories Division of the Israeli Ministry of Health, or AMAR, for the marketing and sale of C-Scan in Israel, which is valid until December 31, 2024.

Negatives

• Check-Cap has a history of losses and a significant accumulated deficit.
• The company's C-Scan product has faced setbacks in clinical trials, delaying its commercialization.
• The merger with Nobul AI Corp. is subject to various conditions and may not be completed.
• If the merger fails, Check-Cap may need to cease operations due to a lack of funding.
• Check-Cap's ordinary shares will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934 if the merger is consummated.
• The company has limited manufacturing experience and capabilities.

Risks

• The consummation of the Business Combination is subject to the satisfaction of certain conditions, which may not be satisfied on a timely basis, if at all.
• Check-Cap's shareholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the consummation of the Business Combination.
• During the pendency of the Business Combination, Check-Cap may not be able to enter into a business combination with another party or issue any equity securities, subject to certain exceptions, because of restrictions in the Nobul BCA, which could adversely affect its financial condition and results of operations.
• Given the cross-border nature of the Business Combination, Check-Cap is and will become subject to a variety of additional risks that may negatively affect the Company's results of operations and financial condition.
• Check-Cap is substantially dependent on its remaining key employees to facilitate the consummation of a strategic transaction.
• If the Business Combination is not completed, and Check-Cap does not pursue an alternative strategic option or liquidation, it expects that it will require significant additional funding in order to complete the development, scale up manufacturing and commercialization of C-Scan or any new products and technology.
• If additional capital is not available, Check-Cap may have to cease operations.
• Check-Cap may be unable to maintain compliance with the Nasdaqs continued listing requirements, which could result in the delisting of its ordinary shares from the Nasdaq Capital Market.
• There is a risk that Check-Cap may be classified as a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences to U.S. investors.
• Our principal offices, research and development facilities, our manufacturing sites and some of our suppliers are located in Israel and, therefore, our business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel.

Future Outlook

Check-Cap's future is contingent on the successful completion of the merger with Nobul AI Corp. or securing alternative strategic options and funding, with potential adjustments to ownership percentages based on Check-Cap's net cash at closing.

Industry Context

The announcement comes amid increasing competition in the colorectal cancer screening market, with companies developing non-invasive technologies based on stool, serum, or molecular diagnostics tests.

Comparison to Industry Standards

• Colonoscopy is the gold standard for colorectal polyp detection, but adherence is low due to its invasiveness.
• Fecal or liquid biopsy tests are patient-friendly but have low sensitivity in detecting pre-cancerous polyps.
• Exact Sciences' Cologuard is a non-invasive stool DNA screening test for colorectal cancer.
• Guardant Health's blood test for detecting colorectal cancer (CRC) in average-risk adults demonstrated 83% sensitivity in detecting individuals with CRC and 90% specificity in both individuals without advanced neoplasia and in those who had a negative colonoscopy result.
• Geneoscopy Inc.'s stool-based diagnostic screening test demonstrated 94% sensitivity for detecting CRC, 45% sensitivity for detecting advanced adenoma (AA), and 88% specificity for no findings on a colonoscopy.

Management Changes

Stakeholder Impact

• Shareholders face potential dilution and reduced influence over the combined company.
• Employees have experienced workforce reductions.
• Customers may face uncertainty regarding the availability of C-Scan.
• Suppliers may be affected by changes in manufacturing and development plans.
• Creditors may be impacted by the company's financial challenges and strategic shifts.

Next Steps

• Obtaining shareholder and regulatory approvals for the merger with Nobul AI Corp.
• Finalizing the terms of the merger and completing the transaction.
• If the merger fails, securing alternative strategic options and funding to continue operations.

Key Dates

Keywords

Merger, Nobul AI, Check-Cap, C-Scan, Delisting, FDA, Clinical Trials, Colorectal Cancer, Financial Results, Strategic Options